Amygdala Neurosciences, Inc.

Industry

  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
See more in Biomedtracker

Latest on Amygdala Neurosciences, Inc.

Scrip

Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune

 
• By Joseph Haas, Ian Haydock, Ying Huang, John Davis, and Sten Stovall

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred between Feb. 13 and 2

In Vivo

Deals Shaping The Medical Industry, March 2017

 
• By Steven Muntner, Beth Allan, Deanna Kamienski, Amanda Micklus, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings Vermillion Inc. Vermillion Inc. grossed $5.6mm through the private sale of 3.75mm common shares at $1.40 (a 6% premium). Investors also received five-year warrants